MT 3534
Alternative Names: MT-3534Latest Information Update: 21 Aug 2025
At a glance
- Originator Pharma Foods International
- Developer Mitsubishi Tanabe Pharma Corporation
- Class Antibodies; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Peptidylarginine deiminase type IV modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
- Preclinical Rheumatoid arthritis
Most Recent Events
- 05 Aug 2025 MT 3534 licensed to Mitsubishi Tanabe Pharma Corpo worldwide (Mitsubishi Tanabe Pharma Corporation pipeline, August 2025)
- 14 Jun 2025 Pharmacodynamic data from a preclinical study in Rheumatoid arthritis presented at the 26th Annual Congress of the European League Against Rheumatism (EULAR 2025)
- 01 Jun 2025 Preclinical trials in Rheumatoid arthritis in Japan (IV)